Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies

Stefan Faderl, Deborah A. Thomas, Susan O'Brien, Guillermo Garcia-Manero, Hagop M. Kantarjian, Francis J. Giles, Charles Koller, Alessandra Ferrajoli, Srdan Verstovsek, Barbara Pro, Michael Andreeff, Miloslav Beran, Jorge Cortes, William Wierda, Ngoc Tran, Michael J. Keating

Research output: Contribution to journalArticle

226 Scopus citations

Abstract

We explored the safety and efficacy of rituximab plus alemtuzumab in patients with relapsed or refractory lymphoid malignancies. Forty-eight patients were treated and were assessable for response (32 with chronic lymphocytic leukemia [CLL], 9 with CLL/prolymphocytic leukemia [PLL], 1 with PLL, 4 with mantle cell leukemia/lymphoma, 2 with Richter transformation). The overall response rate was 52% (complete remission, 8%; nodular partial response, 4%; partial response, 40%). With a median follow-up of 6.5 months (range, 1-20 months), the median time to progression was 6 months (range, 1-20 months); median survival, 11 months (11 + months for responders vs 6 months for nonresponders). Most toxicities were grade 2 or lower and infusion-related. Infections occurred in 52% of the patients. Cytomegalovirus (CMV) antigenemia assays were positive in 27% of the patients, but only 15% were symptomatic and required therapy. The combination of rituximab and alemtuzumab is feasible, has an acceptable safety profile, and has clinical activity with a short course in a group of patients with poor prognoses.

Original languageEnglish (US)
Pages (from-to)3413-3415
Number of pages3
JournalBlood
Volume101
Issue number9
DOIs
Publication statusPublished - May 1 2003
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Faderl, S., Thomas, D. A., O'Brien, S., Garcia-Manero, G., Kantarjian, H. M., Giles, F. J., ... Keating, M. J. (2003). Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood, 101(9), 3413-3415. https://doi.org/10.1182/blood-2002-07-1952